U.S. Markets open in 7 hrs 43 mins

Israeli Cannabis Company To Co-Develop Anti-Inflammatory Products For Respiratory Conditions

Javier Hasse

Univo Pharmaceuticals (TASE: UNVO) will provide medical grade cannabis and cannabis-based products, as well as funding, to the RAMBAM medical center in Haifa, Israel.

The center will be conducting a study aimed at the development of medical cannabis-based products, including anti-inflammatory products for respiratory conditions and pneumonia, such as those caused by the coronavirus.

According to the company, the study has been approved by the Medical Cannabis Unit at the Israeli Ministry of Health.

Both parties are now working in tandem for the study to begin immediately, under the management of Prof. Igal Louria-Hayon, Head of Leukemia Research & Cancer Signaling Lab and Scientific Director at the Medical Cannabis Research & Innovation Center at the RAMBAM health care campus.

Univo will provide RAMBAM with the cannabis and the funding for the study over a period of up to two years, and will be entitled to manufacture and market the resulting products in return for royalty payments to the medical center.

See Also: Canopy Growth, Univo Collaborate On Israeli Medical Cannabis

“We have several research and development collaborations, aiming to harness the uniqueness of the cannabis plant in delivering medical cannabis-based products that we hope could help an array of complicated medical conditions,” said Golan Bitton, CEO of Univo. “In the past, there had been evidence on a possibly positive therapeutic effect of medical cannabis on as an anti-inflammatory agent for conditions related to the respiratory system and pneumonia, and with the outbreak of the COVID-19 pandemic we believe that a way could be found to treat these conditions, and our goal is to find this way as soon as possible."

The Univo-RAMBAM study will examine the anti-inflammatory effects of at least 5 medical cannabis-based formulations in different compositions, on lung cells taken from pneumonia patients. Given such anti-inflammatory effect, these formulations will also be tested for their effect on lung cells taken from COVID-19 patients. Prof. Louria-Hayon expects that the results of the clinical trial are expected in the third quarter of 2020.

Noticias sobre cannabis en Español en El Planteo.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.